PPD Celebrated For Innovative Use Of Technology

Award recognizes government compliance systems for clinical trials

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has won the 2016 OpenText Elite Award for the Most Innovative Project in the Health Sciences Sector. The award, presented at OpenText’s annual Enterprise World conference, recognizes PPD’s use of OpenText in developing electronic trial master files (eTMFs) for use in clinical trials.

“PPD is focused on ensuring that our compliance systems support efficient clinical trial processes to help our clients expedite their research programs to improve patients’ health.”

“Our clients benefit from our innovative use of portal technology to meet government compliance needs,” said Jay Dixon, senior vice president of global quality and compliance for PPD. “PPD is focused on ensuring that our compliance systems support efficient clinical trial processes to help our clients expedite their research programs to improve patients’ health.”

OpenText recognized PPD for developing a global, standardized process and taxonomy to manage the unstructured data acquired or developed during the conduct of a clinical trial. Based on the industry-standard eTMFs, PPD’s version consists of a detailed folder structure, metadata and user groups that provide consistent structure, access and security across all studies for PPD and clients. A single process is employed globally to ensure consistency of the conduct and content of clinical trials, which routinely consist of more than 60,000 documents.

The OpenText Elite Awards recognize outstanding efforts in deriving business value from innovative and successful software deployments using OpenText Enterprise Information Management solutions. PPD was honored among a global field for demonstrating excellence in innovation and implementation of digital solutions.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 16,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about its award-winning eTMF system contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.